Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva PharmaceuticalBusiness Wire • 06/11/26
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth StrategyGlobeNewsWire • 06/10/26
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
Teva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and CareGlobeNewsWire • 06/08/26
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease ChoreaGlobeNewsWire • 06/05/26
Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive ComebacksThe Motley Fool • 06/01/26
TEVA's MAA for Olanzapine LAI in Schizophrenia Accepted in the EUZacks Investment Research • 05/22/26
The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in AdultsGlobeNewsWire • 05/21/26
Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?Zacks Investment Research • 05/19/26
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread ImpactGlobeNewsWire • 05/18/26
Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More.The Motley Fool • 05/15/26
TEVA Q1 Earnings Top Estimates, Branded Drugs Drive Revenues, Stock UpZacks Investment Research • 04/30/26
Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond TargetsGlobeNewsWire • 04/30/26
Teva Pharmaceutical Industries Limited (TEVA) Q1 2026 Earnings Call TranscriptSeeking Alpha • 04/29/26
Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to SayZacks Investment Research • 04/29/26
Teva Surges As Its New Growth Strategy Hits A Key Inflection PointInvestors Business Daily • 04/29/26
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined ExecutionGlobeNewsWire • 04/29/26
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth StrategyGlobeNewsWire • 04/29/26